title: Two enzyme immunoassays and PCR for detection of Helicobacter pylori in stool specimens from pediatric patients before and after eradication therapy.
abstract: This study of pediatric patients was intended to determine the suitability of stool PCR and two antigen enzyme immunoassays (EIAs; Premier Platinum HpSA and the novel FemtoLab H. pylori), which detect Helicobacter pylori antigens in feces, as pretreatment diagnostic tools and especially as posttreatment control. Forty-nine H. pylori-infected children with dyspepsia received eradication therapy. Successful treatment was determined by a negative [(13)C]urea breath test 4 and 12 weeks after discontinuation of therapy. Fecal specimens were collected prior to eradication therapy as well as 4 weeks after the end of treatment. Successfully treated children delivered stool samples at 6, 8, and 12 weeks posttreatment also. Specimens were examined by seminested PCR and Premier Platinum HpSA and were reexamined by both EIAs as soon as FemtoLab H. pylori was available. In the first test series, the overall sensitivities of PCR and Premier Platinum HpSA were 93.0 and 91.1%, respectively. With specimens collected at 4 weeks after treatment, the respective specificities were 68.8 and 79.3%. After longer follow-up periods, however, they gradually increased to 100 and 96.9%, respectively. In the new test series, Premier Platinum HpSA delivered a considerably lower number of false-positive results (4 versus 18), indicating intertest variations. The overall test sensitivity was 94.6%, and the overall specificity was 97.5%. FemtoLab H. pylori showed an excellent performance with an overall sensitivity and specificity of 98.2 and 98.1%, respectively. Thus, in contrast to PCR, both EIAs were shown to be suitable for early posttreatment control.
authors.affiliation: Department of Clinical Microbiology, Hygiene Institute of the University of Vienna, Vienna, Austria. Athanasios.Makristathis@akh-wien.ac.at
authors.forename: A
authors.initials: A
authors.lastname: Makristathis
authors.forename: W
authors.initials: W
authors.lastname: Barousch
authors.forename: E
authors.initials: E
authors.lastname: Pasching
authors.forename: C
authors.initials: C
authors.lastname: Binder
authors.forename: C
authors.initials: C
authors.lastname: Kuderna
authors.forename: P
authors.initials: P
authors.lastname: Apfalter
authors.forename: M L
authors.initials: ML
authors.lastname: Rotter
authors.forename: A M
authors.initials: AM
authors.lastname: Hirschl
mesh_terms: D000293:Adolescent; D000658:Amoxicillin / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000097:blood; D001944:Breath Tests; D002648:Child; D002675:Child, Preschool; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005243:Feces / Q000382:microbiology*; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D016480:Helicobacter pylori / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D007124:Immunoenzyme Techniques; D007074:Immunoglobulin G / Q000097:blood; D009853:Omeprazole / Q000627:therapeutic use; D016133:Polymerase Chain Reaction / Q000379:methods; D013997:Time Factors; D014508:Urea / Q000032:analysis
chemical_list: D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D000658:Amoxicillin; D014508:Urea; D017291:Clarithromycin; D009853:Omeprazole